This article was initially published in NAG Winter Edition 2024 and is now available online for the first time. While some details may have changed since its original publication, all information was ...

(NYSE: PFE) today announced positive topline results from the Phase 3 HER2CLIMB-05 trial of first-line combination therapy with the tyrosine kinase inhibitor TUKYSA ® (tucatinib) in patients with ...

Formula 1 is no longer just a racing series. It is a global entertainment product built on a foundation of speed, spectacle, ...